PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury

医学 冲程(发动机) 安慰剂 神经学 内科学 创伤性脑损伤 神经化学 痴呆 临床全球印象 右美沙芬 物理疗法 麻醉 精神科 疾病 病理 替代医学 工程类 机械工程
作者
Flora M. Hammond,David N. Alexander,Andrew J. Cutler,Stephen D’Amico,Rachelle S. Doody,William Sauvé,Richard D. Zorowitz,Charles S. Davis,Paul Shin,Fred Ledon,Charles Yonan,Andrea E. Formella,João Siffert
出处
期刊:BMC Neurology [Springer Nature]
卷期号:16 (1) 被引量:31
标识
DOI:10.1186/s12883-016-0609-0
摘要

Phase 3 trials supporting dextromethorphan/quinidine (DM/Q) use as a treatment for pseudobulbar affect (PBA) were conducted in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). The PRISM II study provides additional DM/Q experience with PBA secondary to dementia, stroke, or traumatic brain injury (TBI). Participants in this open-label, multicenter, 90-day trial received DM/Q 20/10 mg twice daily. The primary outcome was the Center for Neurologic Study-Lability Scale (CNS-LS), assessing change in PBA episode frequency and severity. The CNS-LS final visit score was compared to baseline (primary analysis) and to the response in a previously conducted placebo-controlled trial with DM/Q in patients with ALS or MS. Secondary outcomes included change in PBA episode count and Clinical Global Impression of Change with respect to PBA as rated by a clinician (CGI-C) and by the patient or caregiver (PGI-C). The study enrolled 367 participants with PBA secondary to dementia, stroke, or TBI. Mean (standard deviation [SD]) CNS-LS score improved significantly from 20.4 (4.4) at baseline to 12.8 (5.0) at Day 90/Final Visit (change, −7.7 [6.1]; P < .001, 95 % CI: −8.4, −7.0). This magnitude of improvement was consistent with DM/Q improvement in the earlier phase-3, placebo-controlled trial (mean [95 % CI] change from baseline, −8.2 [−9.4, −7.0]) and numerically exceeds the improvement seen with placebo in that study (−5.7 [−6.8, −4.7]). Reduction in PBA episode count was 72.3 % at Day 90/Final Visit compared with baseline (P < .001). Scores on CGI-C and PGI-C showed that 76.6 and 72.4 % of participants, respectively, were "much" or "very much" improved with respect to PBA. The most frequently occurring adverse events (AEs) were diarrhea (5.4 %), headache (4.1 %), urinary tract infection (2.7 %), and dizziness (2.5 %); 9.8 % had AEs that led to discontinuation. Serious AEs were reported in 6.3 %; however, none were considered treatment related. DM/Q was shown to be an effective and well-tolerated treatment for PBA secondary to dementia, stroke, or TBI. The magnitude of PBA improvement was similar to that reported in patients with PBA secondary to ALS or MS, and the adverse event profile was consistent with the known safety profile of DM/Q. Clinicaltrials.gov, NCT01799941, registered on 25 February 2013
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
卡卡西完成签到,获得积分20
1秒前
1秒前
qmx完成签到,获得积分10
1秒前
zhinian28完成签到,获得积分10
2秒前
PPSlu完成签到,获得积分10
2秒前
2秒前
2秒前
3秒前
canjian1943完成签到,获得积分10
4秒前
4秒前
chem应助Choi采纳,获得20
4秒前
11完成签到 ,获得积分10
5秒前
6秒前
6秒前
112我的完成签到,获得积分20
6秒前
7秒前
8秒前
canjian1943发布了新的文献求助10
8秒前
我要啃木头完成签到,获得积分10
8秒前
9秒前
zz完成签到,获得积分10
10秒前
传奇3应助kb采纳,获得10
12秒前
12秒前
人间枝头发布了新的文献求助10
13秒前
科研通AI2S应助笨笨小熊猫采纳,获得10
13秒前
13秒前
微笑尔岚完成签到,获得积分10
13秒前
13秒前
阳光以筠发布了新的文献求助10
13秒前
研友_Ze2V48完成签到,获得积分10
14秒前
Lucas应助dspan采纳,获得10
14秒前
一个夏天的年少完成签到,获得积分10
14秒前
15秒前
15秒前
四夕火火火关注了科研通微信公众号
15秒前
16秒前
哈哈哈发布了新的文献求助10
17秒前
JERRI发布了新的文献求助10
17秒前
17秒前
高分求助中
歯科矯正学 第7版(或第5版) 1004
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Semiconductor Process Reliability in Practice 720
GROUP-THEORY AND POLARIZATION ALGEBRA 500
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
Days of Transition. The Parsi Death Rituals(2011) 500
The Heath Anthology of American Literature: Early Nineteenth Century 1800 - 1865 Vol. B 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3229041
求助须知:如何正确求助?哪些是违规求助? 2876786
关于积分的说明 8196563
捐赠科研通 2544175
什么是DOI,文献DOI怎么找? 1374187
科研通“疑难数据库(出版商)”最低求助积分说明 646906
邀请新用户注册赠送积分活动 621640